Project Grant R43AI191888
Award Date 8/1/25
Completion Date 7/31/26
Dollars Obligated $299K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,616 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Shy Therapeutics, LLC to develop a novel class of small molecule antifungal therapies. The project aims to identify and optimize new chemical compounds with potent activity against drug-resistant fungal strains such as Cryptococcus neoformans and Candida auris. Key objectives include using structure-activity relationship...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), is focused on the development of novel benzyl-piperidine antifungal agents to treat intractable Mucorales infections. The $299,946 award to Microbiotix, Inc., a clinical-stage biopharmaceutical company in Worcester, MA, aims to chemically optimize a lead series of benzyl-piperidine compounds to improve their...
- The Project Grant award of $170,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) is focused on the "Structure-Based Design of Antifungal Inhibitors Targeting the Glycosylphosphatidylinositol (GPI) Ethanolamine Phosphate Transferase, MCD4". The research aims to develop new antifungal agents with novel mechanisms of action to address emerging fungal pathogens and growing...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the CFDA 93.855 Allergy and Infectious Diseases Research program, awarded a $300,000 Project Grant to Life Pharms Inc. on September 19, 2025. The grant supports the development of a novel antifungal drug, LP10581, to address the growing public health crisis of invasive, drug-resistant fungal infections. The project aims to further research and testing of this novel compound, which has shown promising in vitro and in vivo...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to support the preclinical development of occidiofungin, a novel antifungal compound, for the treatment of oral and dermal candidiasis. The key objectives are to establish an effective formulation, conduct toxicological and stability studies, and prepare an Investigational New Drug (IND) application...
- This Project Grant award of $348,150.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports the development of Avantamine, a novel antimicrobial chloramine formulation, by Halomine Inc. (doing business as Avantguard). The goal is to optimize Avantamine's efficacy against bacteria found in diabetic foot ulcers to improve treatment and healing outcomes. The project involves evaluating...
- The federal Project Grant award of $299,697 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a novel broad-spectrum antifungal agent targeting cell wall biosynthesis. The goal is to create a mechanistically unique inhibitor of the enzyme 1-3-D-glucan synthase (GS) that demonstrates potent and wide-ranging fungicidal activity, including against echinocandin-resistant...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, has awarded a $300,156 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Intact Genomics Inc., a minority-owned small business. The funding will support research to identify new antifungal compounds with novel mechanisms of action from filamentous fungi. The key objectives are to demonstrate the use of Aspergillus nidulans as a...
- The National Institute of Allergy and Infectious Diseases (NIAID), through its Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $1,000,000 Project Grant to Accure Medical Inc. on April 3, 2025. The grant supports the development of the TheraWaveTM 100, a novel, non-invasive treatment for onychomycosis, a debilitating fungal nail infection that affects over 5% of the global population. The project aims to use targeted, controlled high-frequency energy to...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, will support research to accelerate the discovery of novel antifungal peptides. The $642,775 award to the University of California, Davis will fund a multi-step, high-throughput screening platform leveraging one-bead one-compound (OBOC) combinatorial technology. The goal is to rapidly identify and optimize...